Back to Search
Start Over
Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells.
- Source :
- Chinese Journal of Lung Cancer; 5/20/2019, Vol. 22 Issue 5, p255-263, 9p, 1 Diagram, 4 Graphs
- Publication Year :
- 2019
-
Abstract
- Background and objective Lung cancer is one of the common malignant tumors that impair human health. With the development of epigenetics, the researchers found that enhancer of Zeste homolog 2 (EZH2) is highly expressed in lung cancer tissue and its expression is closely related to the prognosis. EZH2 inhibitor can also enhance the sensitivity of tumor cells to a variety of anti-tumor drugs. The purpose of this study is to investigate the effect of combination of EZH2 inhibitor and gefitinib on the proliferation, apoptosis and migration of Gefitinib-resistant lung cancer cells. Methods PC9 and PC9/AB2 cells were used for this study. CCK-8 and EdU experiment were used to detect combined treatment on cell viability and proliferation activity; Wound healing assay and Transwell chamber experiment were used to determine the effects of combination therapy on cell migration ability; Flow cytometry was used to detect the effect of combination therapy on EZH2 and apoptosis; Western blot was used to observe the effect of combination therapy on epidermal growth factor receptor (EGFR) signaling pathway-related proteins expression. Results In gefitinib-resistant cell line PC9/AB2, gefitinib combined with EZH2 inhibitor GSK343 can significantly inhibit cell viability, reduce cell migration and increase cell apoptosis. At the same time, combination therapy can significantly inhibit the expression of EZH2 and phosphorylation EGFR proteins. Conclusion The combination of EZH2 inhibitor GSK343 and gefitinib sensitize PC9/AB2 cell to gefitinib response. This study also suggests that synergistic therapy plays a role in the reversal of EGFR-tyrosine kinase inhibitor (EGFR-TKIs) resistance in lung cancer. [ABSTRACT FROM AUTHOR]
- Subjects :
- CELL proliferation
ANTINEOPLASTIC agents
APOPTOSIS
BIOLOGICAL assay
CELL lines
CELL receptors
CELL motility
CELLULAR signal transduction
DRUG resistance in cancer cells
ENZYME inhibitors
EPIDERMAL growth factor
FLOW cytometry
LUNG tumors
PHOSPHORYLATION
WESTERN immunoblotting
WOUND healing
CELL survival
GEFITINIB
PHARMACODYNAMICS
Subjects
Details
- Language :
- Chinese
- ISSN :
- 10093419
- Volume :
- 22
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- Chinese Journal of Lung Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 136520587
- Full Text :
- https://doi.org/10.3779/j.issn.1009-3419.2019.05.01